Jacobio Invests $53 Million into Hebecell and its Stem Cell Based CAR-T Therapies
publication date: Sep 1, 2021
Jacobio, a Beijing-Shanghai Pharma, made a $53 million strategic investment in Boston-based Hebecell. Jacobio will collaborate with Hebecel to develop its next-gen natural killer cell therapies based on induced pluripotent stem cells (iPSC-NK). iPSC-NK uses natural killer cells that can be produced indefinitely from iPSC cells, without separating the cells from the patient's blood, a technology that has the potential to offer off-the-shelf CAR-T therapies. Dr. Yinxiang Wang, chairman and CEO of Jacobio, will become Chairman of Hebecell. More details....
Stock Symbol: (HK: 1167)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.